PT  - JOURNAL ARTICLE
AU  - MARKOS ANTONOPOULOS
AU  - STEFAAN W. VAN GOOL
AU  - DIMITRA DIONYSIOU
AU  - NORBERT GRAF
AU  - GEORGIOS STAMATAKOS
TI  - Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy
AID  - 10.21873/anticanres.13315
DP  - 2019 Apr 01
TA  - Anticancer Research
PG  - 2043--2051
VI  - 39
IP  - 4
4099  - http://ar.iiarjournals.org/content/39/4/2043.short
4100  - http://ar.iiarjournals.org/content/39/4/2043.full
SO  - Anticancer Res2019 Apr 01; 39
AB  - Background/Aim: The need for more effective treatment modalities that can improve the clinical outcome of patients with glioblastoma multiforme remains imperative. Dendritic cell vaccination is a fast-developing treatment modality, currently under exploration. Functional immune cell subpopulations may play a role in the final outcome. Materials and Methods: Data from 101 patients drawn from the HGG-2010 trial, including baseline patient characteristics and fluorescence-activated cell sorting of immune cell subpopulations, were analyzed by statistical and machine-learning methods. Results: The analysis revealed strong correlations between immune profiles and overall survival, when the extent of resection and the vaccination schedule were used as stratification variables. Conclusion: A systematic, in silico workflow detecting strong and statistically significant correlations between overall survival and immune profile-derived quantities obtained at the start of dendritic cell vaccination was devised. The derived correlations could serve as a basis for the identification of prognostic markers discriminating between potential long- and short-term survivors of patients with glioblastoma multiforme.